Actively Recruiting
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
Led by Yizhuo Zhang · Updated on 2025-02-20
300
Participants Needed
1
Research Sites
669 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.
CONDITIONS
Official Title
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 0 to less than 18 years, any gender
- Tumor diagnosis confirmed by histopathology or bone marrow cytology
- Patients receiving first-time treatment
- ECoG score less than or equal to 2
- Expected survival time longer than 8 months
- Parent or guardian has signed informed consent
You will not qualify if you...
- Presence of immunodeficiency disease
- Diagnosis of a second tumor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Suying Lu
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
S
Suying Lu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here